Xtant Medical Holdings, Inc. (XTNT) has recently reported strong financial results for the second quarter of 2025 and announced strategic initiatives aimed at focusing on its core biologics business.

**Recent Financial Performance (Q2 2025)**
*   On August 12, 2025, Xtant Medical announced its second quarter 2025 financial results.
*   The company reported total revenue of $35.4 million, marking an 18% increase compared to the same period in 2024.
*   Xtant Medical achieved a positive net income of $3.6 million in Q2 2025, a significant improvement from a net loss of $3.9 million in the prior year's second quarter.
*   Adjusted EBITDA for the quarter was $6.9 million, compared to an Adjusted EBITDA loss of $0.6 million in Q2 2024.
*   Gross margin improved to 68.6% for Q2 2025, up from 62.1% in the comparable period of 2024.
*   The company generated $1.2 million in cash from operations in Q2 2025, contrasting with cash used in operations of $5.1 million in Q2 2024.
*   Operating expenses saw a reduction to $19.7 million from $21.5 million in Q2 2024.
*   Increased orthobiologics sales and licensing revenue, which included $5 million in Q2 2025, were primary drivers for the revenue growth.

**Guidance and Outlook**
*   Following its strong Q2 performance, Xtant Medical raised its full-year 2025 revenue guidance to a range of $131 million to $135 million, projecting an 11-15% growth over fiscal year 2024. This is an increase from its prior guidance of $127 million to $131 million.
*   The company anticipates an additional $5 million in royalty revenue during the second half of 2025.
*   Xtant Medical aims to achieve operational cash positivity and does not foresee the need for additional external capital raises.

**Strategic Initiatives and Business Developments**
*   **Asset Divestiture:** On July 8, 2025, Xtant Medical announced definitive agreements to sell its non-core Coflex® and CoFix® spinal implants and all Outside U.S. (OUS) businesses to Companion Spine for approximately $19.2 million. This transaction includes $11 million in cash at closing and $8.2 million in short-term seller financing, intended to focus the company on its core businesses, reduce outstanding debt, and enhance liquidity.
*   **Product Launches:**
    *   The company commercially launched OsteoFactor Pro™, an allogeneic growth factor solution designed to improve bone healing, on May 28, 2025.
    *   Xtant Medical also launched Trivium™, a next-generation demineralized bone matrix (DBM) allograft.
    *   With the launch of OsteoFactor Pro™, Xtant Medical became the first vertically integrated company to offer solutions across all five major orthobiologic categories.
    *   Other recent product launches mentioned include SimplyMax, SimplyGraph, OsteoVive Plus, and Fibrex.
*   **Vertical Integration:** Xtant Medical has become a fully vertically integrated biologics company, manufacturing all its products in-house, contributing to improved gross margins.
*   **Market Expansion:** The company is expanding its focus into adjacent markets such as surgical repair, sports medicine, and chronic wound care.
*   **Distribution Network:** Xtant Medical maintains a broad distribution network, including 450 Integrated Delivery Network (IDN) contracts and over 670 independent distributors.

**Upcoming Events**
*   Xtant Medical is scheduled to participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, where its CEO Sean Browne and CFO Scott Neils will present and hold one-on-one meetings. The company's presentation was made available on-demand starting September 5, 2025.